3/3
04:11 pm
ngne
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Medium
Report
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
3/3
04:01 pm
ngne
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/27
01:33 pm
ngne
Neurogene (NGNE) is now covered by Canaccord Genuity Group Inc.. They set a "buy" rating and a $200.00 price target on the stock.
Medium
Report
Neurogene (NGNE) is now covered by Canaccord Genuity Group Inc.. They set a "buy" rating and a $200.00 price target on the stock.
2/26
04:14 pm
ngne
Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome [Yahoo! Finance]
High
Report
Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome [Yahoo! Finance]
2/26
04:01 pm
ngne
Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome
High
Report
Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome
2/5
07:30 am
ngne
Neurogene to Participate in Upcoming Investor Conferences
Medium
Report
Neurogene to Participate in Upcoming Investor Conferences
2/4
04:01 pm
ngne
Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
1/26
09:26 am
ngne
Neurogene (NASDAQ:NGNE) is now covered by analysts at Lifesci Capital. They set an "outperform" rating and a $50.00 price target on the stock.
Medium
Report
Neurogene (NASDAQ:NGNE) is now covered by analysts at Lifesci Capital. They set an "outperform" rating and a $50.00 price target on the stock.
1/13
08:03 am
ngne
Neurogene (NASDAQ:NGNE) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $70.00 price target on the stock.
Medium
Report
Neurogene (NASDAQ:NGNE) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $70.00 price target on the stock.
1/12
08:55 am
ngne
Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome [Yahoo! Finance]
Medium
Report
Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome [Yahoo! Finance]
1/12
07:00 am
ngne
Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome
Medium
Report
Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome
1/5
07:30 am
ngne
Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference
High
Report
Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference